CAR T-CELL THERAPY
FOR LYMPHOMA
A complete guide for patients and families โ what CAR T-cell therapy is, which lymphoma types it treats, how the treatment process works, eligibility criteria, how it compares to stem cell transplant and bispecific antibodies, and how to access it in China and India.
analyticsAt a Glance
- check_circleCAR T-cell therapy reprograms a patient's own T cells to recognise CD19 on lymphoma cells โ creating a living therapy that can persist and work even when chemotherapy has failed.
- check_circleThree products are formally approved for relapsed or refractory DLBCL โ axicabtagene ciloleucel, lisocabtagene maraleucel, and tisagenlecleucel โ with strong long-term remission data in responding patients.
- check_circleChina has approved domestic CD19 CAR-T products and runs active next-generation trials โ offering equivalent outcomes at 60-80% lower cost than Western markets.
- check_circleCytokine release syndrome and neurological toxicity are the principal risks and require specialist management โ centre capability matters as much as product choice.
What CAR T-Cell Therapy Is and How It Works in Lymphoma
CAR T-cell therapy is a form of cellular immunotherapy in which a patient's own T cells are collected, genetically modified to express a chimeric antigen receptor (CAR), expanded in a manufacturing laboratory, and infused back to seek out and destroy lymphoma cells. The CAR is engineered to recognise CD19 โ a protein expressed on the surface of B-cell lymphoma cells โ making the modified T cells precise hunters within the patient's body.
โUnlike chemotherapy, which damages cancer cells based on general growth rate, CAR T-cell therapy creates immune cells that recognise your specific lymphoma cells and destroy them โ even when chemotherapy resistance has already developed.โ
The Four Steps of CAR-T Manufacture
Leukapheresis collects T cells from blood. The CAR gene is inserted via viral vector. Cells are expanded to billions in a GMP laboratory over 2-4 weeks. The final product is infused after lymphodepleting chemotherapy. Each patient's product is unique โ manufactured only for them.
Why CD19 Is the Target
CD19 is expressed on virtually all B-cell lymphomas and on normal B cells โ making it an accessible and reliable target. After CAR-T infusion, both lymphoma cells and normal B cells are depleted (B-cell aplasia), which is manageable with immunoglobulin replacement. The trade-off is well understood and accepted clinically.
The Role of Lymphodepleting Chemotherapy
Before CAR-T infusion, patients receive a short course of fludarabine and cyclophosphamide conditioning. This depletes the existing immune population, creating space for CAR-T cells to expand and reducing competition for the cytokines they need to survive and proliferate.
Why Relapsed and Refractory Lymphoma Is Different
When lymphoma relapses or is refractory to first-line treatment, repeat chemotherapy often has reduced efficacy. CAR-T therapy bypasses chemotherapy sensitivity entirely โ using immune recognition rather than cytotoxic drug mechanisms โ which is why it can work when chemotherapy has already failed.
Approved CAR-T Products for Lymphoma
Four CD19-directed CAR-T products have received major regulatory approvals for B-cell lymphoma. Each has a distinct manufacturing platform and approved indication.
| Product | Target / Developer | Key Approved Indication | Key Efficacy |
|---|---|---|---|
| Axicabtagene ciloleucel (Yescarta) | CD19 / Kite-Gilead | r/r large B-cell lymphoma โฅ2 prior lines | ZUMA-1: 58% ORR; durable remissions in ~40% at 5 years |
| Lisocabtagene maraleucel (Breyanzi) | CD19 / Bristol Myers Squibb | r/r large B-cell lymphoma โฅ2 prior lines; 2L transplant-ineligible | TRANSFORM: superior PFS vs standard salvage |
| Tisagenlecleucel (Kymriah) | CD19 / Novartis | r/r DLBCL โฅ2 prior lines; r/r B-ALL paediatric | JULIET: 40% ORR; 12-month DOR 65% in responders |
| Domestic products (China) | CD19 / multiple developers | r/r large B-cell lymphoma (NMPA approved) | Comparable ORR to global products; lower cost |
| Next-gen dual-target CD19/CD22 | CD19+CD22 / China trials | CD19-loss relapse; high-risk r/r B-cell | Trial โ may be free; active Chinese enrolment |
Which Lymphoma Types Are Treated With CAR T-Cell Therapy?
CD19-directed CAR-T is primarily approved for aggressive B-cell lymphomas. The strongest evidence base is in DLBCL and related large B-cell lymphomas.
Diffuse Large B-Cell Lymphoma (DLBCL) โ Primary Indication
DLBCL is the most common aggressive lymphoma globally and the indication with the strongest CAR-T evidence. All three globally approved products have primary approval for DLBCL. The ZUMA-7, TRANSFORM, and PILOT trials established CAR-T as second-line therapy for transplant-ineligible relapsed DLBCL, bringing the technology earlier in the treatment pathway.
Follicular Lymphoma (Indolent)
Axicabtagene and tisagenlecleucel have expanded approvals for relapsed or refractory follicular lymphoma after three or more prior lines. The ZUMA-5 trial showed 91% ORR and 76% complete response โ high response rates even in this typically less aggressive subtype.
Mantle Cell Lymphoma
Brexucabtagene autoleucel (Tecartus) is approved for r/r mantle cell lymphoma. The ZUMA-2 trial showed 87% ORR and 62% complete response โ particularly important for a disease where BTK inhibitor failure historically left very limited options.
Primary Mediastinal B-Cell Lymphoma and High-Grade B-Cell Lymphoma
Both are included in the DLBCL approvals for axicabtagene and lisocabtagene. These subtypes have historically been challenging โ particularly PMBCL in younger patients โ and CAR-T offers a cellular approach that can achieve durable remissions.
The CAR T-Cell Treatment Journey, Step by Step
From eligibility assessment to post-infusion monitoring โ the complete pathway for patients undergoing CAR T-cell therapy for lymphoma.
- 1
Eligibility Assessment and MDT Review
Performance status, organ function (cardiac, hepatic, renal, pulmonary), disease burden, prior treatment lines, and overall fitness reviewed by a multidisciplinary team. Not all patients with relapsed lymphoma are CAR-T candidates.
- 2
Leukapheresis โ T-Cell Collection
T cells collected from blood via apheresis in a 3-6 hour session. No anaesthesia. The collected cells are sent to the manufacturing facility and the patient waits during the manufacturing period.
- 3
Bridging Therapy (If Needed)
Patients with rapidly progressing or bulky disease may receive bridging chemotherapy or radiation during the 2-4 week manufacturing period to control disease while awaiting the CAR-T product.
- 4
Lymphodepleting Chemotherapy
3-5 days of fludarabine and cyclophosphamide conditioning before infusion. Clears existing immune cells to create space for CAR-T expansion and reduces competition for growth factors.
- 5
CAR-T Infusion and Inpatient Monitoring
Single IV infusion, typically 30-60 minutes. Inpatient monitoring for CRS and ICANS for a minimum of 7-14 days at the treating centre. High-dependency or ICU-level monitoring required at specialist centres.
- 6
Response Assessment and Follow-Up
PET-CT response assessment at approximately 1 month and 3 months post-infusion. Long-term follow-up for B-cell aplasia, immunoglobulin replacement, and late effects.
CAR-T vs Bispecific Antibodies for Relapsed Lymphoma
Both CAR-T and bispecific antibodies (e.g., epcoritamab, glofitamab) target CD19 or CD20 on lymphoma cells. Choosing between them depends on disease tempo, prior treatment, and practical considerations.
CAR-T Cell Therapy
- Single-course therapy โ one infusion, potential durable remissionResponding patients can achieve long-term remissions without ongoing treatment.
- Superior durable complete response rates~40% of DLBCL patients treated with CAR-T maintain remission at 5 years.
- Works after prior bispecific antibody failureCD19 CAR-T may remain active in patients who have progressed on bispecifics targeting different epitopes.
- Manufacturing time allows bridging for controlled diseaseSuitable when disease burden is manageable during the 2-4 week wait.
Bispecific Antibodies
- Off-the-shelf โ no manufacturing waitAvailable immediately โ critical when disease is rapidly progressing.
- Outpatient or less intensive monitoringCRS with bispecifics is generally less severe than with CAR-T โ some patients managed outpatient.
- Ongoing dosing maintains disease controlContinuous suppression of disease โ suitable when ongoing treatment is preferred.
- Available when CAR-T manufacturing fails or patient is ineligiblePractical alternative when T-cell collection quality is poor or patient fitness excludes CAR-T.
CAR T-Cell Therapy Costs for Lymphoma: China vs Western Markets
China's domestic CAR-T manufacturing significantly reduces the product cost. The full treatment cost includes more than the drug alone.
CD19 CAR-T โ r/r DLBCL (Drug Cost)
- China (domestic approved product)USD 80,000โ165,000
- India (NexCAR19 โ CD19)USD 40,000โ70,000
- USA (Yescarta / Kymriah)USD 350,000โ465,000
Total Treatment Cost Including Hospital Stay (China)
- China โ drug + 6-week stay + supportive careUSD 120,000โ200,000
- USA โ drug + hospital + all feesUSD 450,000โ600,000
Key Evidence Numbers
- 58%Overall Response Rate โ Axicabtagene (ZUMA-1)40% complete response at 2 years. Landmark approval data for r/r large B-cell lymphoma.
- ~40%Patients in Durable Remission at 5 Years (DLBCL)Long-term follow-up from ZUMA-1 and similar trials โ real potential for extended disease-free survival.
- 600+Active CAR-T Trials in ChinaIncluding next-generation dual-target, allogeneic, and solid tumour programmes โ the largest trial ecosystem globally.
- 6-10 weeksTotal In-Country Time RequiredCell collection + manufacturing wait + conditioning + infusion + monitoring. Plan carefully.
How CancerFax Supports Your CAR-T Journey for Lymphoma
CAR-T for lymphoma requires careful clinical matching, honest eligibility assessment, and detailed practical coordination.
- 1
Medical Record and Eligibility Review
We review pathology, flow cytometry, molecular reports, prior treatment lines, performance status, and organ function to assess CAR-T suitability honestly.
- 2
Approved vs Trial Pathway Assessment
For DLBCL and other approved indications, we assess both approved product pathways and active Chinese trials โ clarifying cost difference and practical timelines.
- 3
Pre-Travel Eligibility Confirmation
Reports submitted to the relevant hospital team before any travel decision. Written confirmation of eligibility and proposed pathway before commitment.
- 4
Full International Coordination
Documentation, translation, visa, travel, hospital communication, interpreter, and follow-up coordination with the home haematology team.
Related Guides and Resources
Explore related CAR-T topics and cancer treatment guides.
Frequently Asked Questions
About CAR-T for Lymphoma
Which lymphoma types can be treated with CAR T-cell therapy?
CAR-T is approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (after โฅ3 prior lines), mantle cell lymphoma, primary mediastinal B-cell lymphoma, and high-grade B-cell lymphoma. These are all B-cell lymphomas expressing CD19. Hodgkin lymphoma (which is CD19-negative) is not routinely treated with current approved CAR-T products.
How many prior treatment lines are needed before CAR-T?
Approved indications generally require disease that is relapsed or refractory after two or more prior lines of therapy, including an anti-CD20 antibody and an anthracycline. More recent approvals (lisocabtagene) also cover second-line treatment for transplant-ineligible patients whose disease progresses after first-line therapy. Eligibility is assessed individually โ prior treatment history, performance status, and organ function all matter.
Can I have CAR-T therapy in China if I'm from another country?
Yes. Major Chinese cancer centres including Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, and National Cancer Center Beijing treat international patients with CAR-T. Eligibility depends on the same clinical criteria as domestic patients. CancerFax coordinates the eligibility review, documentation, and full logistical support for international patients.
What is cytokine release syndrome and how serious is it?
Cytokine release syndrome (CRS) occurs when CAR-T cells activate rapidly and trigger a broad immune response โ releasing cytokines that cause fever, low blood pressure, and in severe cases, organ stress. Most CRS is grade 1-2 (manageable with supportive care and tocilizumab); severe grade 3-4 CRS occurs in 10-30% of patients and requires ICU-level care. This is why CAR-T must be given at a specialist centre with dedicated monitoring capability.
How does CancerFax help with CAR-T access for lymphoma?
CancerFax reviews medical records, pathology, and flow cytometry to assess CAR-T suitability. We identify appropriate approved or trial pathways in China or India based on diagnosis and prior treatment, submit reports for hospital eligibility review, and coordinate all practical arrangements from documentation and translation to travel, hospital communication, and post-treatment follow-up.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is CAR T-Cell Therapy the Right Next Step for Your Lymphoma?
Share your pathology, flow cytometry, and treatment history โ our haematology team will assess whether CAR-T is clinically appropriate and identify the best pathway in China or India for your specific diagnosis.
This information is for patient education and navigation only. All treatment decisions must be made with a qualified haematologist or oncologist.